NCT02244242View on ClinicalTrials.gov

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

PHASE4CompletedINTERVENTIONAL
Enrollment

493

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

August 31, 1999

Conditions
Prostatic Hyperplasia
Interventions
DRUG

Tamsulosin hydrochloride

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02244242 - Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter